期刊文献+

Exendin-4介导的猪髋动脉内皮细胞NO释放与细胞内钙离子浓度变化的关系 被引量:3

Relationship between nitric oxide release from pig iliac endothelial cells caused by Exendin-4 and change in intracellular calcium
下载PDF
导出
摘要 目的观察Exendin-4(Ex-4)介导的猪髋动脉内皮细胞(PIEC)内一氧化氮(NO)释放与钙离子变化的关系,探讨Ex-4影响内皮细胞功能的机制。方法免疫荧光法检测确认PIEC上存在胰高血糖素样肽-1受体(GLP-1R)。NO荧光探针(DAF-FM DA)标记细胞内NO,荧光酶标仪检测Ex-4作用内皮细胞后不同时间点[加药前(0h),加药后1、2、3、4、5、6、7、8、9、10、11、12h,共13个时点]细胞内NO释放情况;钙离子荧光探针(Fura-2 AM)标记细胞内钙,荧光酶标仪检测细胞内3个不同时段(0~30min,4~4.5h,8~8.5h)钙浓度变化情况;评价Ex-4诱导PIEC释放NO与细胞内钙的关系。结果 PIEC上有GLP-1R表达。Ex-4引起PIEC内NO增加,且有时间依赖关系,与0h比较,4h开始NO明显增高(P〈0.05),8h时细胞内NO含量较其他各时点均明显增高(P〈0.05)。Ex-4干预后0~30min、4~4.5h和8~8.5h 3个时段细胞内钙均较对照组高(2.042±2.115 vs 0.634±0.352,P〈0.01;0.413±0.154 vs 0.113±0.111,P〈0.01;0.309±0.133 vs 0.063±0.120,P〈0.01)。Ex-4干预PIEC后NO释放前期前段(0~30min),细胞内钙逐渐上升(拟合曲线:y=0.106x+1.326);NO释放中期前段(4~4.5h,y=0.003x+0.374)和NO释放后期前段(8~8.5h,y=-0.001x+0.324)细胞内钙浓度虽同NO一样也高于对照组,但没有明显的变化趋势。结论 Ex-4可增加内皮细胞内NO释放,该过程与细胞内钙变化密切相关。 Objective To study the effects of Exendin-4(Ex-4) on the function of endothelial cells by investigating the relationship of Ex-4 induced nitric oxide(NO) release from pig iliac endothelial cells(PIEC) and changes in intracellular calcium.Methods Glucagon-like peptide-1 receptor(GLP-1R) was confirmed to be present in PIEC by immunofluorescence assay.Intracellular NO production was probed using DAF-FM DA,and then measured with fluorescence microplate reader at the time-points of 0,1,2,3,4,5,6,7,8,9,10,11 and 12h.The intracellular Ca2+ concentration was probed with Fura-2 AM at 0-30min,4-4.5h and 8-8.5h and measured with fluorescence microplate reader.The relationship between Ex-4 induced NO release in PIEC and intracellular Ca2+ concentration was evaluated.Results GLP-1R was expressed in PIEC.Ex-4 increased the intracellular NO level in PIEC in a time-dependent manner.NO level was significantly higher 4 hours after Ex-4 treatment compared with that of 0-hour group(P〈0.05).The intracellular NO level reached the top value 8 hours after Ex-4 treatment(P〈0.05).The intracellular Ca2+ concentrations were significantly higher during the periods of 0-30min,4-4.5h and 8-8.5h after Ex-4 treatment than those of their control groups(2.042±2.115 vs 0.634±0.352,P〈0.01;0.413±0.154 vs 0.113±0.111,P〈0.01;0.309±0.133 vs 0.063±0.120,P〈0.01).During the period of 0-30min after Ex-4 treatment,the intracellular Ca2+ concentration increased gradually(fitted curve: y=0.106x+1.326);while during the periods of 4-4.5h(y=0.003x+0.374) and 8-8.5h(y=-0.001x+0.324) after Ex-4 treatment,the intracellular Ca2+ concentrations,and the NO levels were higher than those of their control groups,but without significant variation.Conclusions Ex-4 may increase the NO release in endothelial cells,and intracellular calcium ions may participate in the process.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2012年第9期859-863,共5页 Medical Journal of Chinese People's Liberation Army
关键词 一氧化氮 内皮细胞 胰高血糖素样肽-1受体激动剂 nitric oxide; endothelium cells; glucagon-like peptide-1 receptor agonist
  • 相关文献

参考文献30

  • 1Bogdan C. Nitric oxide and the immune response[J]. Nat Immunol, 2001, 2(10): 907-916.
  • 2Tripathi P. Nitric oxide and immune response[J]. Indian J Biochem Biophys, 2007, 44(5): 310-319.
  • 3Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability[J]. Diabetes Care, 2011, 34(Suppl 2): $279-$284.
  • 4金玉翠,申传安,柴家科.胰高血糖素样肽1的结构及生物学作用研究进展[J].解放军医学杂志,2011,36(8):875-878. 被引量:8
  • 5陆菊明.糖尿病研究现状及展望[J].解放军医学杂志,2010,35(7):777-780. 被引量:41
  • 6Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists[J]. AmJ Cardiol, 2011, 108(3 Suppl): 33B-41B.
  • 7Sivertsen J, Rosenmeier J, Holst JJ, et al. The effect of glucagon- like peptide-1 on cardiovascular risk[J]. Nat Rev Cardio, 2012, 9(4): 209-222.
  • 8Mundil D, Cameron-Vendrig A- Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects[J]. Diab Vasc Dis Res, 2012, 9(2): 95-108.
  • 9Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatidetwice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database [J]. Diabetes Care, 2011, 34( 1): 90-95.
  • 10Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide- 1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells [J]. Diabetologia, 2010, 53 (10): 2256-2263.

二级参考文献93

共引文献52

同被引文献91

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部